StreetAlpha
13F holdings · Q3 2026

Avoro Capital Advisors

New York, NY · files as Avoro Capital Advisors LLC
Know the moment Avoro Capital Advisors filesYou follow Avoro Capital Advisors An email or push as soon as its next 13F reaches the SEC, with every stock it bought, sold and trimmed. Next 13F due by Feb 15, 2027
Filed
Holdings as of Sep 30, 2026Filed Nov 16, 2026Next filing due Feb 15, 2027CIK 1633313

Avoro Capital Advisors reported 30 stocks worth $9.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (15.4%), ASND (11.9%) and KRYS (9.9%). Compared with Q2 2026, the fund opened new positions in DMRA, ABVX and SCTX, added to AVTX and trimmed UTHR, ASND and ARWR.

Latest filing: what Avoro Capital Advisors did in Q3 2026

vs Q2 2026
Filed 13F-HRView on SEC ↗
5 new1 added15 trimmed1 sold outBought about $239M · sold about $364M
New 5
Added 1
Trimmed 15
See all 15 →
Sold out 1
  • Galecto Inc$98.4M

Dollar changes use the share change at the quarter end price. New and sold out show the whole position.

Reported value$9.7B−13.0% vs last quarter
Stocks held305 new · 1 sold out
Top 5 weight56.6%fairly concentrated
Turnover6%of the portfolio changed

Portfolio at a glance

share of reported value · Q3 2026
🔒 A free account shows every holding, what the fund sold and its options.Create free account

Holdings

#StockValueWeightSharesChangeShares, 8 qtrsHeld
1
UTHR
United Therapeutics Corp Del
$1.5B15.4%2.8M−22K (−1%)8 of 8
2
ASND
Ascendis Pharma A/s
$1.2B11.9%5M−61K (−1%)2 of 8
3
KRYS
Krystal Biotech Inc
$961M9.9%2.9MNo change8 of 8
4
ARGX
Argenx SE
$959M9.9%1MNo change8 of 8
5
MDGL
Madrigal Pharmaceuticals Inc
$924M9.5%1.8MNo change8 of 8
6
KYMR
Kymera Therapeutics Inc
$836M8.6%7.5MNo change8 of 8
7
ARWR
Arrowhead Pharmaceuticals in
$720M7.4%11M−356K (−3%)8 of 8
8
RVMD
Revolution Medicines Inc
$440M4.5%2.1M−152K (−7%)4 of 8
9
CYTK
Cytokinetics Inc
$323M3.3%4.9M−100K (−2%)3 of 8
10
DFTX
Definium Therapeutics Inc
$268M2.8%7M−139K (−2%)3 of 8
🔒 20 more holdings in this filing. Create a free account or sign in to see them all.

Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.

Sold out

held in Q2 2026, gone in Q3 2026
StockValue last quarterShares sold
GALECTO INC
$98.4M3.8M

Reported value

last 8 quarters
$7.1BQ4 '24
$6.4BQ1 '25
$5.7BQ2 '25
$7.7BQ3 '25
$10.2BQ4 '25
$10.2BQ1 '26
$11.1BQ2 '26
$9.7BQ3 '26

The value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.

Filings for Q3 2026

straight from the SEC
FiledFormQuarter
Nov 16, 202613F-HRQ3 2026SEC filing ↗

Other superinvestors

All hedge fund holdings →

Avoro Capital Advisors 13F FAQ

What does Avoro Capital Advisors own?

Avoro Capital Advisors reported 30 stocks worth $9.7B in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are UTHR (15.4%), ASND (11.9%) and KRYS (9.9%). The table above lists every position in the filing (the top 10 without an account).

What did Avoro Capital Advisors buy and sell in Q3 2026?

Compared with Q2 2026: 5 new positions, 1 added to, 15 trimmed and 1 sold out. New positions include DMRA, ABVX and SCTX.

When will Avoro Capital Advisors file its next 13F?

Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.

How much is Avoro Capital Advisors's portfolio worth?

The Q3 2026 filing reports $9.7B in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.

For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.